BIOTRONIK launches PK Papyrus covered coronary stent in the US

Huge Two-Day Clean Sweep Auction July 24-25th. Click Here to Bid!

Current Location:
>
>
> This Story

Forward Printable StoryPrint Comment
advertisement

 

advertisement

 

Cardiology Homepage

AHRA and Canon Medical Systems support medical imaging innovation with the 12th annual putting patients first program

European Society of Cardiology hosting digital summit in Tallinn

Abbott receives U.S. approval of next-generation MitraClip, bringing new enhancements to Abbott's leading MitraClip platform

Telehealth Technology to reduce hospital readmissions and improve outcomes for cardiac disease patients

FDA approves Bayer's Gadavist (gadobutrol) injection as first contrast agent for use in cardiac MR in adult CAD patients

New technology improves atrial fibrillation detection after stroke

New study of ultrasound enhancing agents in echocardiography reaffirms safety profile of LUMASON

Johns Hopkins Medicine researchers identify health conditions likely to be misdiagnosed

Team approach to cardiac care increases chance of surviving heart attack complications

Philips supports CNIC to shape the future of cardiac care

BIOTRONIK launches PK Papyrus covered coronary stent in the US

Press releases may be edited for formatting or style
LAKE OSWEGO, Ore., April 10, 2019 /PRNewswire/ -- BIOTRONIK today announced the United States (US) commercial launch of the PK Papyrus® covered coronary stent system for use in the emergency treatment of acute coronary perforations.1,2

More than 800,000 percutaneous coronary intervention procedures are performed annually in the US3 and fewer than 8,000 require a covered stent, classifying PK Papyrus as a Humanitarian Use Device. The ultrathin strut, single-stent design and unique electrospun polyurethane membrane expands treatment options and is designed to reduce the high rate of adverse outcomes associated with coronary artery perforations.

Story Continues Below Advertisement

Servicing GE Nuclear Medicine equipment with OEM trained engineers

We offer full service contracts, PM contracts, rapid response, time and material,camera relocation. Nuclear medicine equipment service provider since 1975. Click or call now for more information 800 96 NUMED



"The availability of PK Papyrus marks a long-overdue advancement in the field of interventional cardiology," said Ryan Walters, President of BIOTRONIK, Inc. "Clinicians can now rely on a low-profile covered stent during critical cardiac emergencies. In situations where every second counts, physicians can trust PK Papyrus to deliver quickly. BIOTRONIK's covered stent is designed to save more lives and to help avoid emergency bypass surgeries, which come with increased risk for patients and can be costly for hospitals. This is innovation that matters for hospital administrators, physicians and their patients, who deserve the best outcomes."

PK Papyrus is the first FDA-approved device for the treatment of acute coronary artery perforations in nearly two decades. It is available in 17 sizes and is the only 5 French compatible4 covered coronary stent on the US market. BIOTRONIK's covered stent is 58 percent more flexible,5 and has a 23 percent smaller crossing profile compared to Graftmaster,6 which has a layered dual-stent design and is the only other covered coronary stent available in the US.

Following the February 2019 approval and availability of Orsiro, the only FDA-approved ultrathin strut drug-eluting stent, the launch of PK Papyrus further strengthens BIOTRONIK's vascular intervention portfolio in the US. PK Papyrus received CE mark in 2013 and was approved for use by the FDA in late 2018. For more information about PK Papyrus or the Institutional Review Board process required to use the covered stent, visit www.PKPapyrus.com or call 800-547-0394.


About BIOTRONIK
BIOTRONIK is a leading medical device company that has been developing trusted and innovative cardiovascular and endovascular solutions for more than 50 years. Driven by a purpose to perfectly match technology with the human body, BIOTRONIK innovations deliver care that saves and improves the lives of millions diagnosed with heart and blood vessel diseases every year. BIOTRONIK is headquartered in Berlin, Germany, and represented in over 100 countries. BIOTRONIK has US offices in New York City and Lake Oswego, Oregon.

Back to HCB News
  Pages: 1

Cardiology Homepage


You Must Be Logged In To Post A Comment